Loading patent…
AssigneeCHO Plus, Inc.
InventorsLawrence Forman, Kathy Ngo
Estimating the term…
This disclosure provides a technology for adapting host cells to maximize production and improve quality of viral vectors and particles. Cell hybrids are formed from parental cell lines, and divided or cloned into multiple aliquots for testing. Aliquots are chosen that have high production capacity and phenotypic features for virus production, such as an optimal level of intracellular organelles, and used to establish producer cell lines. The producer cells can be genetically altered to express a transgene that encodes viral elements for production of the viral vectors or particles with a therapeutic payload. The hybrid producer cells generate more viral vectors or particles per cell with higher functional titer, thereby lowering the cost of production of pharmaceutical agents for use in gene therapy and immunization.
A process for establishing a producer cell line for high efficiency production of viral vectors or particles, the process comprising:
A process for establishing a producer cell line for high efficiency production of viral vectors or particles, the process comprising:
A producer cell line that has been adapted for high efficiency production of viral vectors or particles according to the following process:
A line of producer cells wherein each cell is a hybrid of two or more parental cells from a starter cell population, wherein the producer cells comprise an expressible transgene that encodes one or more elements of a virus, whereby the cells are configured to produce a viral vector or particle containing said elements.
Dependencies are inferred from the claim text.